This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

The market for GSK plc's ( LON:GSK) shares didn't move much after it posted weak earnings recently. We did some digging, and ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

GSK sales hampered by slump in demand for key vaccine - The drugmaker said sales of Arexvy fell sharply in the third quarter, ...

GlaxoSmithKline is to sell off its famous bedtime malted milk drink Horlicks in the UK, and will also consider exiting a pharma business, its cephalosporins antibiotics franchise. This gloomy news ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac ...

UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

GSK has confirmed plans to sell its Horlicks business in the UK and close the site where the malted drink is made. As well as shutting the site in Slough, the pharmaceuticals giant said it will ...